Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors

Autor: Renata Ferrarotto, Laura Testa, Rachel P. Riechelmann, Marina Sahade, Luiz T. Siqueira, Frederico P. Costa, Paulo M. Hoff
Jazyk: angličtina
Rok vydání: 2013
Předmět:
Zdroj: Rare Tumors, Vol 5, Iss 3, Pp e35-e35 (2013)
Druh dokumentu: article
ISSN: 2036-3605
2036-3613
DOI: 10.4081/rt.2013.e35
Popis: The role of chemotherapy in well differentiated neuroendocrine tumors (NET) has been questioned. It was recently demonstrated that everolimus and sunitinib have activity in low and intermediate grade pancreatic NET. The aim of this study was to evaluate the activity of capecitabine and oxaliplatin (CapOx) combination in treating NET in an unselected population. In this regard, we retrospectively evaluated 24 patients diagnosed with metastatic NET treated with CapOx at two Brazilian institutes that are reference centers in cancer care. Tumor response was measured by RECIST criteria. Median age at diagnosis was 56 years, 71% had ECOG 0 or 1, the majority of tumors were primary from pancreas (67%) followed by lung (17%), and 29% were functional. According to WHO classification criteria, 25% were grade 1, 37.5% grade 2 and 37.5% grade 3. Most patients received CapOx as second-line therapy, with a median of 6 cycles. Twenty-nine percent of patients had partial response by RECIST criteria. No association was observed between response rate and tumor grade, primary site or line of CapOx. The median time to progression was 9.8 months and median time to treatment failure was 12.1 months. Seventy-five percent of patients are alive at the time of this analysis; therefore, median overall survival was not reached. The CapOx combination was shown to be active in an unselected population with metastatic NET and may be a good platform for the incorporation of the newer molecular targeted agents being investigated for the treatment of this entity.
Databáze: Directory of Open Access Journals
Externí odkaz: